Navigation Links
Amarin to Present at Two Upcoming Investor Conferences
Date:2/22/2011

MYSTIC, Conn. and DUBLIN, Feb 22, 2011 Amarin Corporation plc (Nasdaq: AMRN) today announced that members of its senior management team will be presenting at two investor conferences on March 2, 2011.

Joseph Zakrzewski, Executive Chairman and Chief Executive Officer, is scheduled to present at the CITI 2011 Global Healthcare Conference on Wednesday, March 2, 2011 at 2:00 pm ET. This conference will be held at the Hilton New York City. A live audio webcast of the presentation will be available at http://www.veracast.com/webcasts/citigroup/healthcare2011/75211419.cfm.

John Thero, President, is scheduled to present at the RBC Capital Markets' Healthcare Conference on Wednesday, March 2, 2011 at 4:35 pm ET. This conference will be held at the New York Palace Hotel in New York City. A live audio webcast of the presentation will be available at http://www.wsw.com/webcast/rbc129/amrn.

About AmarinAmarin Corporation plc is a clinical-stage biopharmaceutical company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company's lead product candidate is AMR101 (icosapent ethyl, formerly called ethyl icosapentate). On November 29, 2010, the Company reported positive, statistically significant top-line results from the MARINE trial, the first of its Phase 3 clinical trials of AMR101. In the MARINE trial, AMR101 was investigated as a treatment for very high triglycerides (>500 mg/dL). AMR101 is presently being investigated in a second Phase 3 clinical trial, the ANCHOR trial, for the treatment of patients on statin therapy with high triglycerides (≥200 and <500mg/dL) with mixed dyslipidemia. The MARINE trial was, and the ANCHOR trial currently is, conducted under Special Protocol Assessment (SPA) agreements with the U.S. Food and Drug Administration (FDA). Amarin also has next-generation lipid candidates under evaluation for preclinical development.Investor Contact Information: Stephen SchultzInvestor Relations and Corporate CommunicationsAmarin CorporationIn U.S.: +1 (860) 572-4979 investor.relations@amarincorp.com Lee M. Stern The Trout Group In U.S.: +1 (646) 378-2922 lstern@troutgroup.comMedia Contact Information: David Schull or Martina Schwarzkopf, Ph.D. Russo Partners In U.S.: +1 (212) 845-4271 or +1 (212) 845-4292 (office) +1 (347) 591-8785 (mobile) david.schull@russopartnersllc.commartina.schwarzkopf@russopartnersllc.com
'/>"/>

SOURCE Amarin Corporation plc
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia
2. Amarin Corporation Appoints Colin W. Stewart as President and Chief Executive Officer
3. Amarin to Present at UBS Life Sciences Conference
4. Amarin Corporation to Host Investor Conference Call on Wednesday, November 10, 2010
5. Amarin to Present at Canaccord Genuity Cardiovascular, Diabetes & Obesity Conference
6. Amarin Prices Public Offering of American Depositary Shares
7. Amarin Announces Underwriters Exercise of Over-Allotment Option
8. Amarin Announces Successful Completion of Offering of American Depositary Shares
9. Amarin Provides 2010 Year-End Review to Shareholders
10. Amarin to Present at the Leerink Swann Hot Topics in Therapeutics Roundtable Conference
11. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2017)... 18, 2017 EpiVax, Inc. ("EpiVax") ... and immune engineering, today announced a new ... (H7N9) vaccine. ... influenza and presents a challenge for traditional ... to be effective. Using state-of-the-art bioinformatics and molecular ...
(Date:9/12/2017)... YORK , Sept. 12, 2017   EcoVadis , the leading ... has published the first annual edition of its Global CSR Risk and ... companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 ... ... Index ...
(Date:9/12/2017)... , Sept. 12, 2017  ValGenesis Inc., ... Solutions (VLMS), is pleased to announce the appointment ... member of its Board of Directors and Chairman ... VLMS enables life science companies to manage their ... use of paper in this process. Furthermore, ValGenesis ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare ... program management, will showcase a range of technology and learning solutions at the ... Convention and Expo to be held October 14–18, 2017 at the Mandalay Bay ...
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally recognized health ... expanded their existing home health joint venture through an agreement, effective October 1, ... joint venture home health company with Asante, delivering clinically integrated care, for the ...
(Date:10/12/2017)... PA (PRWEB) , ... October 12, 2017 , ... ... is the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B ... York City on October 11, 2017. , The annual award competition recognizes editorial and ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand Rapids-based ... and Brightest in Wellness® by Best and Brightest. OnSite Wellness will be honored ... 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection Hotel, ...
Breaking Medicine News(10 mins):